Our results indicate that aberrant midline crossing by motor neuron cell bodies and axons in mice lacking Robo1 and Robo2 are not interdependent and that DCC contributes to axon, but not cell body ...

Lexeo Therapeutics, Inc, a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced positive interim data across all dose cohorts of ...

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

Lexeo Therapeutics has posted updated data in Friedreich ataxia (FA) patients, linking a gene therapy to improvements on outcomes the biotech plans to use as co-primary endpoints in a ...

Friedreich’s ataxia (FA) is a neurodegenerative disease most people have never heard of, and it remains widely misunderstood —and for the hundreds of Canadians who live with it, the lack of ...

We found that mice lacking cystatin B develop myoclonic seizures and ataxia, similar to symptoms seen in the human disease. The principal cytopathology appears to be a loss of cerebellar granule ...